SHOULD CARDIOLOGIST PRESCRIBE AN SGLT-2 INHIBITOR?

Sina Jame, Mary E. Jame,Laurence McMahon,Elif Oral,Peter Hagan,Melvyn Rubenfire,Richard Weinberg

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2019）

引用 0|浏览22

暂无评分

摘要

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a new class of diabetes medications with significant cardiovascular benefit. There is uncertainty regarding the appropriate prescribing service. This survey assessed the practice patterns of cardiologists, endocrinologists and primary care

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要